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Keywords:
fragment could act as amarker for skeletal muscle atrophy [3,4] or path-
ologic cardiovascular events [5]. However, in the aforementioned study a
decameric oligopeptide common for both skeletal and cardiac titin iso-
formswas chosen as an analyte. Also, peptides less then 5 kDa are very ef-
ﬁciently eliminated trough kidneys resulting in short plasma half-life of
few minutes.Titin
myocardial infarction
serum biomarker
ELISACardiovascular diseases are globally a major cause of mortality, with
myocardial infarction (MI) presenting as the most frequent acute clini-
cal ﬁnding. Early diagnosis is key component for the effective treatment
and management of this malady. Modern diagnosis of MI relies on the
electrocardiography and the measurement of serum biomarkers [1].
Measurement of cardiac troponins has been shown to be superior to
all other clinically available biomarkers, such as myoglobin, the MB-
fraction of creatine kinase (CK-MB), for the diagnosis of myocardial in-
farction. However, the cardiac troponin assays have their limitations.
Firstly, easy release of cytosolic troponin pool in non-coronary-related
situations might complicate differential diagnosis of MI. Moreover, in
patients with renal dysfunction troponin I as well troponin T elevations
are found that cannot be linked to myocardial injury [2]. Finally, clinical
practice would proﬁt from increased sensitivity of these assays, in par-
ticular directly after symptom onset. Thus, search for new MI bio-
markers remains clinically relevant task. (See Fig. 1.)
We have chosen titin as a biomarker candidate for the MI diagnosis.
Titin being the largest protein discovered so far is tightly integrated into
the striatedmuscle lattice, thus leakage of this protein into bloodstream
would require myoﬁbrillar degradation and not only a transient muscleland Ltd. This is an open access articlstress. Indeed it was shown that the metalloproteinase cleaved titin
Based on this provisowe have developed a prototype sandwich-type
ELISA for the complete cardiac titin speciﬁc N2B region (98 kDa,
residues 3500–4373 in UniRef Q8W242). The N2B exon is included in
cardiac titin isoforms only, because it is skipped by exon skipping in
skeletal muscle tissues [6]. Antigen-puriﬁed polyclonal antibodies pro-
duced in rabbit and goat (available also from www.myomedix.com)
were used for capture and detection, respectively. This prototype
assay was tested on sera from non-ST segment elevation (NSTEMI),
STEMI patients and healthy controls (Table 1). Patient blood samples
used in this studywere collected at presentation to the cardiac intensive
care unit. All the patients underwent a clinical assessment that included
medical history, physical examination, 12-lead ECG, continuous ECG
monitoring, pulse oximetry, standard blood test, chest radiography
and an echocardiography. MI was diagnosed and classiﬁed according
current guidelines [7,8]. The study was approved by Lithuanian Bioeth-
ics Committee (Protocol number 158,200–2011/09) and conducted in
compliance with the Declaration of Helsinki.
A one-way ANOVA was conducted to determine if the log-
transformed N2B serum levels were different in MI patient and
control groups. Neither the presence nor absence of 3 outliers had an
effect on statistical conclusion validity, thus one-way ANOVA presented
herewas performed after excluding outliers. Datawas normally distribut-
ed for each group and there was homogeneity of variances. N2B serum
levels were signiﬁcantly different between different patient groups, F (2,
95) = 19,966; p b .0001, Ω2 = 0.28. N2B serum levels were highest in
STEMI (1.307 ± 0.23 log(ng/mL)), followed by NSTEMI (1.16 ± 0.40
log(ng/mL)) and lowest in control group (0.70 ± 0.04 log(ng/mL)).
Tukey post hoc analysis revealed that the increase in N2B serum levels
in STEMI (0.60, 95% CI (0.38 to 0.83), p b 0.0001) and in NSTEMI (0.46,
95% CI (0.22 to 0.70), p b 0.0001) when compared to control group was
statistically signiﬁcant. Assay demonstrated outstanding sensitivity ande under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.Heart-speciﬁc N2B fragment of titin is a sensitive serologicalmarker for cardiomyocyte injury inMI. A. Distribution of N2B serum levels in STEMI, NSTEMIpatients and control sera. A
one-way ANOVA revealed signiﬁcant differences between groups (p-value b 0.001) and post hoc comparisons using the Tukey post hoc test revealed that STEMI and NSTEMI had
signiﬁcantly higher serum N2B levels than control sera. B. ROC curve for the developed assay. Serum N2B levels can be used as a sensitive and speciﬁc tool in diagnosing MI. C.
Dynamics of N2B and TnI biomarkers. Measured biomarker values were plotted against the transformed time from onset of symptoms. Smoothing line for each maker was drawn to
emphasise the differences in temporal dynamics of studied biomarkers. Note the time-independent nature of N2B levels in MI patients, in contrast to the single peak shaped
distribution proﬁle of TnI levels. D. Comparison of assay sensitivity in early and late detection of MI. Patient sera were divided into early (b 6 h) and late (N 6 h) MI samples according
the time from the reported onset of symptoms and classiﬁed as positive or negative, based on the reference values for the MI diagnosis (either manufacturer reported MI rule-in
criteria or 99th percentile of healthy population). N2B has comparable sensitivity to hsTnT in early MI diagnosis, and outperforms this assay in late diagnosis (explanations in text).
233Correspondencespeciﬁcity in distinguishing MI (B), at the cut-off of 11.32 ng/mL, with
78.6% sensitivity and 93.7% speciﬁcity. This assay was as well efﬁcient in
recognising NSTEMI (AUC: 0.788; 62.9% sensitivity, 93.7% speciﬁcity) or
STEMI (AUC: 0.946, 89.8% sensitivity and 93.7% speciﬁcity).
Nextwe evaluated how this assay performs in respect to other clinical
biomarkers for heart damage. Serum N2B levels moderately correlated
with serum TnI values (r = 0.479, p N 0.0001, N = 83) and MB-CK
(r = 0.41, p N 0.001 N= 69), but not with hsTnT and BNP levels.
Distribution of serum N2B values in respect to time from onset
of symptoms revealed rather ﬂat proﬁle (Panel C), whereas TnI and
MB-CK (data not shown) where peaking around 10–18 h after patient
reported onset of symptoms. This raises a potential use of developed
assay for the early recognition of MI. To investigate this, patient cohort
was divided according the time from onset of symptoms to blood
sampling into early diagnosis (≤6 h) and late (N6 h) groups. Specimens
were classiﬁed into positive and negative according the clinical MI
rule-in criteria. Cut-off value for N2B (11.32 pg/mL) was chosen
from ROC analysis. Sensitivity of developed test was compared
using McNemar's test. N2B outperformed MB-CK in early diagnosis of
MI (34.8% vs. 81.5%, p-value 0.012) and showed a trend towards the
higher sensitivity than TnI (p-value 0.065). Noteworthy N2B test wasmore often positive in late MI diagnosis then hsTnT (p-value 0.096)
(Panel D).
The data suggest a clinical usefulness of detection of cardiac speciﬁc
titin fragment in blood as a marker for the myocardial damage. Using
developed prototype assaywe could demonstrate a signiﬁcant elevation
of biomarker in bothNSTEMI and STEMI patient groupswhen compared
to non-diseased individuals. The assay showedoutstanding ROC charac-
teristics for all studied subgroups. Obtained results indicate that serum
levels of N2B might have different kinetics, than troponin T upon myo-
cardial injury. Possibly, because titin is a very large protein and released
titin N2B fragments and released titin fragments rapidly accumulate
during kidney failure. Clearly, more studies are needed on the nature
of titin fragmentation during myocardial necrosis.
We also noted that percutaneous coronary interventions were
more often applied in NSTEMI patients with elevated N2B levels
(92% vs. 61%, p-value 0.028 χ2-test), whereas no other tested bio-
marker had a statistically signiﬁcant relation to PCI. If not only cor-
relative, this might indicate that elevated titin N2B warrants PCI.
Clearly, investigating larger variety of MI patients sera from differ-
ent clinical settings is needed to further address the relevance of
this pilot data set.
Table 1
Clinical characteristics of patients studied.
NSTEMI STEMI Control
Sex Male 10 10 9
Female 25 40 7
Age years 64,6 ± 11,6 66,6 ± 13 45,8 ± 12
N2B pg/mL 19,2 ± 16,7 31,7 ± 43,6 5,6 ± 6,5
BMI kg/m2 26,8 ± 4,4 27,2 ± 3,9
Arterial hypertension 80.0% 67.3%
Diagnosed coronary diseasse 23.0% 12.2%
Dyslipidemia 89.0% 69.4%
Smoking 14.0% 32.7%
Previous acute coronary syndrome None 27 41
Angina pectoris 0 4
Myocardial infarction 6 4
Unstable angina pectoris 2 0
Previous acute coronary intervention None 31 44
Coronary artery bypass surgery 1 1
Percutaneous coronary intervention 3 4
Time from onset of symptoms (median hours) 24 9
TnT pg/mL 914 ± 1870 904 ± 1389
CK-MB ng/mL 21,8 ± 44 54,9 ± 101
BNP pg/mL 415 ± 537 604 ± 846
Coronarography ﬁndings Not perfomed 0 1
No pathology 1 0
one-vessel coronary disease 14 14
two-vessel coronary disease 6 14
three-vessel coronary disease 9 14
left main trunk disease 2 6
coronary sclerosis 3 0
Thrombolysis 0.0% 22.4%
Percutaneous coronary intervention 68.6% 95.9%
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